anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Historically, symptomatic PAD was treated with surgical bypass; however endovascular treatment is now the first line treatment when medical therapy fails. Several endovascular treatment options exist including percutaneous transluminal angioplasty (PTA), stenting with bare metal or drug-eluting stents (DES), cutting balloons, atherectomy, laser debulking. Moreover, drug-coated balloon（DCB）has emerged as a potential treatment option, combining acute restoration of vessel patency by balloon dilatation with long term maintenance of such patency by the anti-proliferative drug delivered by the balloon surface. Results from numerous clinical studies with paclitaxel coated balloons have been reported for the safety and efficacy for peripheral artery diseases.

Besides Medtronic IN.PACT Admiral, other DCBs approved for marketing in Chinese Mainland include Acoart (Acotec, China), Reewarm ® PTX (endovastec, China), Ultrafree (ZYLOX, China). Although DCBs had been widely applicable after registration, there are still lack of clinical data and evidence in the real world condition of Chinese population. Therefore, the data collection can also further expand and understand the experience of using DCB in a real world patient population in China, especially for the surveillance of safety events, in order to ensure the long-term application safety in Chinese population. Moreover, this data collection aims to perform regularly clinical follow up to guide the standardized diagnosis and treatment of patients post-operatively, in order to achieve the maximum clinical benefits of these patients, as well as improve the development of the field of peripheral artery disease treated by drug-coated balloon.
In vitro method for determining the overall antiradical defense potential of a living organism or of a physical, chemical or biological agent. In vitro method for determining the overall antiradical defense potential of a living organism or of a physical, chemical or biological agent. The method uses free radicals to induce cell lysis, then analysis of this lysis, and the new feature is that it includes hydrolysis of cellular material before or during release (in a reaction medium) of free radicals from a free radical generator. ACTIVITY : Nootropic; Neuroprotective; Antiparkinsonian. No biological data is given. MECHANISM OF ACTION : Free radical inhibitor.
FIELD: veterinary science. SUBSTANCE: method involves formation of granules from lactose powder in fluidized layer. Biomaterial containing vaccine strain of Newcastle disease virus is applied on granules by spraying. High rate of drying in sparing regime ensures to preserve the main immunobiological properties of Newcastle disease virus. Invention can be used in production of biological preparations for poultry immunization against Newcastle disease. EFFECT: improved technological effectiveness of method of preparing granulated lactose-containing vaccine against Newcastle disease in poultry. 1 tbl, 2 ex
OBJECTIVES: The aims of this study were to describe the baseline estimated blood loss (EBL) in surgery and transfusion rate in patients undergoing cytoreductive surgeries for ovarian malignancy, and identify perioperative variables associated with blood loss and transfusion.
METHODS: A retrospective cohort study at a single institution was performed that included patients with known or suspected ovarian malignancy undergoing cytoreductive surgery between 2016 and 2021. t tests, χ2 tests, and multiple logistic regression analyses were used.
RESULTS: Among 44 patients meeting inclusion criteria, 61% received perioperative blood transfusion. There were significant differences in EBL and preoperative hemoglobin levels between patients who did and did not receive transfusion (EBL 442.6 vs 236.8 mL, P = 0.0008; preoperative hemoglobin 10.2 vs 11.2 g/dL, P = 0.049). After adjusting for preoperative hemoglobin, the risk of transfusion increased for each additional 200 mL of EBL (odds ratio [OR] 3.8, 95% confidence interval [CI] 1.5-9.5). Stratified by race, the association between EBL and transfusion risk remained statistically significant only for non-Latinx White patients (OR 6.1, 95% CI 1.7-21.9), who made up 77% of the study population, but not for patients of other races and ethnicities (OR 1.0, 95% CI 0.16-6.42).
CONCLUSIONS: Perioperative blood transfusion is common in patients undergoing cytoreductive surgery. In this study, EBL and preoperative hemoglobin levels were significantly associated with transfusion receipt. Clinicians should optimize hemoglobin levels and intraoperative blood conservation strategies to reduce the need for transfusion. The results also highlight the importance of considering racial and ethnic differences when developing strategies to reduce transfusion risk.
The present disclosure describes an imaging system configured to determine the accuracy of anatomical measurements obtained from image data. The system may include an ultrasound transducer configured to acquire echo signals in response to ultrasound pulses transmitted toward a target region. The system can also include a graphical user interface configured to display a biometric tool widget, such as a caliper, for acquiring measurements of anatomical features within the target region from at least one image frame generated from the ultrasound echoes. The system can also include one or more processors configured to: a confidence measure indicative of the accuracy of the measurement is determined. The processor can be further configured to: causing the graphical user interface to display a graphical indicator corresponding to the confidence measure. The processor can implement one or more neural networks and can derive additional information, such as gestational age or weight, from the acquired anatomical measurements.
The utility model relates to a forehead patch. At present, forehead patches on the market are all in a conventional rectangular structure, and the forehead patches with the structure can only be used for applying beauty aiming at the main part of the forehead and cannot look after more corner parts, so that the forehead patches have defects. The utility model discloses outside-in includes non-woven fabrics layer, thin grid layer, hydrogel layer and pearly-lustre rete in proper order, thin grid layer be the synthetic polymer net of silk screen, natural fiber net, artificial fiber net or plastic net, the forehead paste and form a lower convex part in the lower part, the both sides of lower convex part form the arc portion of pasting of symmetry. The utility model discloses a forehead pastes and sets up thin grid layer between hydrogel layer and non-woven fabrics layer, makes whole have better toughness and elasticity, is difficult for tearing, also can play the effect of laminating and skin of compacting. The combination of the hydrogel layer and the pearlescent film layer can fade fine lines, preserve moisture and nourish. The unique forehead pastes the structure can be better the more positions of laminating.
The invention discloses a 1, 2-benzisothiazolin-3-one water suspension preparation and a preparation method thereof, wherein the 1, 2-benzisothiazolin-3-one water suspension preparation remarkably improves the environmental protection and safety of products by introducing hydroxylated 1, 2-benzisothiazolin-3-one, polylactic acid microcapsules and natural extract auxiliary components. The hydroxylation of 1, 2-benzisothiazolin-3-one enhances water solubility and biodegradability, reduces environmental risks, and reduces skin irritation. The polylactic acid microcapsule technology effectively encapsulates active ingredients, controls the release rate, and improves the stability and the shelf life of the preparation. Natural extracts such as tea tree oil and rosemary oil provide additional antibacterial and antioxidant effects. In addition, the citric acid/sodium citrate buffer system ensures stability of the formulation over a suitable pH range, reducing irritation to the skin. The whole preparation process is carefully designed, the consistency and the repeatability of the preparation are ensured, and the requirements of the cosmetic industry on efficient, safe and environment-friendly preservatives are met.
Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO \>10 ppm.
The present invention relates to a recording medium capable of minimizing laterality errors in a hospital information system (HIS) and a use thereof. A recording medium according to the present invention is an algorithm of detecting and correcting in real time a laterality error between a recording medium and patient information in a hospital information system and includes an input module and a correction module. To this end, it has been confirmed that the laterality error between a medical examination name and a radiological report is detected and corrected by using a macro-program in a radiological report. When the recording medium of the present invention is used, the real laterality error (discordance between a medical examination name and a radiological report) of 0.05% or less all was detected and corrected in the hospital information system. If the recording medium is used in future, a laterality error may be prevented from occurring. Thus, the recording medium and the system using the same according to the present invention may greatly reduce laterality errors, so that exact medical service may be provided to a patient. In addition, recently issued accurate medicine and patient protection may be more actively prepared, so that it is possible to induce the productivity and competitiveness of medical service (for example, productivity increase and medical service improvement by medical treatment and its support) to be increased.
The present invention relates to a slightly acidic environment-sensitive and ketal-linked gefitinib-fluoroboronbipyrrole derivative and a preparation method therefor and a medical use thereof. The molecular structure of the derivative is as described in formula (I) of the description. In particular, the present invention relates to a gefitinib-fluoroboronbipyrrole derivative and a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a photosensitiser, especially the use in the treatment of cancers. In a normal tissue environment, due to the interplay between the gefitinib group and the fluoroboronbipyrroline derivative, the compound has a lower cytotoxicity. However, in the extracellular slightly-acidic environment of the tumour tissue, ketals hydrolyse and the fragments of the fluoroboronbipyrrole derivative obtained by hydrolysis exhibit an extremely high photosensitive activity, while a gefitinib derivative obtained by hydrolysis can be used as an inhibitor of epidermal growth factor receptor (EGFR) tyrosinase for inhibiting tumour growth. The compounds can be prepared into photodynamic therapeutic and chemotherapeutic double-efficacy anticancer drugs targeting both the tumour extracellular slightly-acidic environment and the EGFR tyrosine kinase.
Cisplatin, a highly effective chemotherapeutic drug for various human cancers, induces irreversible sensorineural hearing loss as a side effect. Currently there are no highly effective clinical strategies for the prevention of cisplatin-induced ototoxicity. Previous studies have indicated that short-term cisplatin ototoxicity primarily affects the outer hair cells of the cochlea. Therefore, preventing the entry of cisplatin into hair cells may be a promising strategy to prevent cisplatin ototoxicity. This study aimed to investigate the entry route of cisplatin into mouse cochlear hair cells. The competitive inhibitor of organic cation transporter 2 (OCT2), cimetidine, and the sensory mechanoelectrical transduction (MET) channel blocker benzamil, demonstrated a protective effect against cisplatin toxicity in hair cells in cochlear explants. Sensory MET-deficient hair cells explanted from Tmc1Δ;Tmc2Δ mice were resistant to cisplatin toxicity. Cimetidine showed an additive protective effect against cisplatin toxicity in sensory MET-deficient hair cells. However, in the apical turn, cimetidine, benzamil, or genetic ablation of sensory MET channels showed limited protective effects, implying the presence of other entry routes for cisplatin to enter the hair cells in the apical turn. Systemic administration of cimetidine failed to protect cochlear hair cells from ototoxicity caused by systemically administered cisplatin. Notably, outer hair cells in MET-deficient mice exhibited no apparent deterioration after systemic administration of cisplatin, whereas the outer hair cells in wild-type mice showed remarkable deterioration. The susceptibility of mouse cochlear hair cells to cisplatin ototoxicity largely depends on the sensory MET channel both ex vivo and in vivo. This result justifies the development of new pharmaceuticals, such as a specific antagonists for sensory MET channels or custom-designed cisplatin analogs which are impermeable to sensory MET channels.
The invention provides a tetracyclic triterpene compound. The tetracyclic triterpene compound is obtained by performing separation of a positive phase silica gel column and a negative phase silica gel column from traditional Chinese medicine mother grasses and purifying by means of efficient liquid chromatogram. The research verifies that the tetracyclic triterpene compound plays a role in antioxidation through genes of sod 1 and sod 2 and can be used for increasing Sir2 gene expression to prolong the replication service life of yeast. The invention also provides an application in preparation of anti-aging medicines. The preparation and the application provide an evidence for developing the compound to become anti-aging medicines and anti-aging health-care products. A structural general formula of the tetracyclic triterpene compound is shown in the specification.
Equine endometrosis is a degenerative and predominantly fibrotic condition resulting from progressive and irreversible multifactorial causes that influence the endometrium of mare. Tissue remodeling in the equine endometrium occurs as part of the pathogenesis of endometrosis, a process characterized by a shift in extracellular matrix (ECM) components. The relationship between matrix metalloproteinases and their specific inhibitors is crucial for the remodeling process. Collagen play a significant role in maintaining a healthy uterus and may promote fibrotic processes. The aim of this study was to quantify endometrial collagen deposition using picrosirius 25 red (PSR) staining, and to evaluate gene expression of collagen type 2 (COL-2) and 3 (COL-3), matrix metalloproteinases 1 (MMP-1) and 2 (MMP-2), their tissue inhibitor (TIMP-2), and tumor necrosis factor (TNF-α) in the endometrium of mares with different grades of fibrosis. The samples (n = 34) were classified into three categories based on the frequency and distribution of fibrosis-related changes in the endometrium: Category I (healthy endometrium, n = 12), Category II (moderate fibrosis, n = 12), and Category III (severe fibrosis, n = 10). Collagen quantification demonstrate a substantial proportional increase (P < 0.0001) in collagen deposition across Category I (11.72 ± 1.39 %), Category II (17.76 ± 1.29 %), and Category III (24.15 ± 1.87 %). In transcript evaluations, higher COL-2 expression was found in Category II than in mares classified as Category I or III. MMP-1 showed increased transcript expression in Category II compared to Category III endometrial samples. Higher expression of MMP-2 was detected in Category III than in Category I and II. TIMP-2 showed lower mRNA expression in Category III vs Category I and II. However, TNF-α gene expression was higher in Category II than in Categories I and III. This study demonstrates that endometrial evaluation using PSR can play an important role in routine analyses for the detection and objective quantification of collagen in endometrial tissues. Additionally, this study demonstrated through gene expression analysis that MMP-1 may be linked to physiological endometrial remodeling. In contrast, MMP-2 could be associated with fibrogenesis in the endometrium, which is regulated by the inhibitor TIMP-2. Furthermore, COL-2 and TNF-α could be considered as biological markers involved in the progression endometrosis in mares. As such, the results of this study may contribute to the development of future antifibrotic therapies that aim to delay or even reverse the pathological remodeling of the extracellular matrix in the uterus, in addition to optimizing the diagnosis and prognosis of endometrial fibrosis in mares.
The invention discloses Eclipta prostrate for cooling blood and stopping bleeding. The Eclipta prostrate for cooling blood and stopping bleeding is prepared from the following raw materials by weight part: 140-150 of Eclipta prostrate, 1-2 of platycladus orientalis leaves, 1-2 of rehmannia leaves, 2-3 of cassia mimosoides, 1-2 of purslane, 1-2 of Cirsium japonicum, 1-2 of loofah, 2-3 of Cryptolepis sinensis, 1-2 of Calathodes oxycarpa, 1-2 of Grangea maderaspatana, 1-2 of ginseng, and 28-30 of raspberries. According to the invention, a variety of traditional Chinese medicines with the efficacy of cooling blood and stopping bleeding are employed to process the Eclipta prostrate, so that its blood cooling and bleeding stopping efficacy can be prominent and significantly enhanced. Eclipta prostrate and raspberries are mixed to conduct scenting, so that Eclipta prostrate can have the flowery flavor. After brewing, the flowery flavor is strong, and does not disperse after long-term brewing. The Eclipta prostrate provided by the invention has a good blood cooling effect.
Many genes are identified as being p53-regulated which were not heretofore known to be p53-regulated. This includes both genes whose expression is induced and genes whose expression is repressed by the expression of wild-type p53. Monitoring expression of these genes is used to provide indications of p53 status in a cell. Such monitoring can also be used to screen for useful anti-cancer therapeutics, as well as for substances which are carcinogenic.  Defects in p53 can be bypassed by supplying p53 induced genes to cells.  Defects in p53 can also be bypassed by supplying antisense constructs to p53-repressed genes.
PURPOSE:To obtain a physiologically active substance, having hyaluronidase inhibitory action and antiviral action and useful as antiallergic agent and antiviral agent, by extracting Ganoderma lucidum Karst. with water and collecting an ingredient containing hexouronic acid from the resultant extract. CONSTITUTION:About 20pts.wt. water is added to 1pt.wt. fine powder of Ganoderma (botanical name; Ganoderma lucidum Karst.) and extracted at 90-100 deg.C for several hours and concentrated to about 20 times to give an extract essence, which is then dissolved in water in an amount of about 100 times. Ethanol in an amount of about 5 times is then added to precipitate a physiologically active substance. The resultant precipitates are then fractionated by using a column, e.g. Sephadex G-100, etc., to afford the aimed physiologically active substance flowing out to a fraction containing hexouronic acid by distilling away the solvent. The physiologically active substance is stable to heat (90 deg.C for 10min), readily soluble in water and insoluble in ethanol and present in the fraction of the hexouronic acid different from a protein fraction.
The present invention relates to the technical field of organic chemistry, particularly to the technical field of organic macromolecular compounds, and more particularly to the technical field of processes for obtaining chitosan from exuviae of Cherax Quadricarinatus and Cambarellus Montezumae. It aims to establish the extraction method of the existing chitosan in the exuvia thereof, due to the impact that this natural polymer has on the production of plastic products for the industry that requires packaging to cover its products for sale, adapting a specific method for the extraction of the chemical component that considers seven technical steps, unlike other inventions. The said method consists of eliminating free water in the exuvia, the physical characterization of the solid phase, the demineralization, the deproteinization, the solid phase, the deacetylation, and the final physical characteristics thereof. Also, it eliminates the depigmentation phase because it does not affect t he physical features of chitosan, unlike other types of raw materials. The process considers an organic material as a residue in aquaculture crops, obtained naturally with the growth of organisms. Further, the chitosan applies as a polymer for producing bioplastics for industries that require degradable plastics used in the packaging of their products during their marketing.
Investigators enrolled 36 patient and randomized them to different group (HT, QT). at the first evaluation examination findings noted, PROMs (patient reported outcome measurements) questioned, thigh circumference measured, flexor and extensor thigh muscle strength recorded with help of Humac CYBEX Norm (CSMI, 2004) device. After these examinations and preparations all patients operated by the same surgeon who is familiar with both technique. The same surgical technique and fixation method used for both groups. At 1st year follow-up all evaluations PROMs (İKDC,lysholm,VAS) and measurements repeated. Back to the sports rates and postoperative complications compared between HT-QT.
The derivatives have the general formula (I) wherein R1? is an optionally mono or polyhalogenated aliphatic acyl group, a benzoyl or phenacetyl group which may carry on the phenyl residue one to three halogeno or alkyl substituents, an alcoxycarbonyl group, a phenoxy or benzyloxy-carbonyl group, an alkyl carbomoyl, phenylcarbamoyl or benzyl carbamoyl group, R2? is an optionally mono or polyhalogenated alkyl group, a phenyl or aralkyl group which may carry on the phenyl residue from one to three substituents selected amongst halogeno, hydroxy, mthoxy or benzyloxy, an indolyl, indolyl-methyl, cycloalkyl-alkyl or cycloalcenyl-alkyl group, R3? is a hydrogen atom or a methyl group and R4? is a hydrogen atom or a methyl group. Application to medicaments.